Phase III study investigating Ibrutinub and Venetoclax for the treatment of patients with relapsed/refractory mantle cell lymphoma.
Dr Paul Eliadis AM was recently involved in a global Phase III study investigating Ibrutinub and Venetoclax for the treatment of patients with relapsed/refractory mantle cell lymphoma. You can read the full study and results by clicking here. On the study, Dr Eliadis AM noted: “It is always a privilege to work alongside my colleagues across the globe to help improve treatment approaches for patients… Read More »Phase III study investigating Ibrutinub and Venetoclax for the treatment of patients with relapsed/refractory mantle cell lymphoma.